The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
COVID-19 vaccination has played a pivotal role in coping with the COVID-19 pandemic by providing a powerful tool to curb the spread of the virus, reduce severe illness and hospitalizations, and ultimately save lives and facilitate a return to normal daily routines. As COVID-19 vaccination has become more widespread and more individuals have recovered from the infection, COVID-19 has entered an endemic disease phase. This phase is characterized by a less severe and more stable pattern of infection within certain regions, similar to the predictability of seasonal influenza. In this endemic era, COVID-19 vaccines may appear to be less important, and many people are reluctant to receive COVID-19 vaccination for various reasons, including the fear of adverse events. However, COVID-19 remains a major public health problem, in that the incidence rate of new COVID-19 infections is still high and the morbidity and mortality in high-risk populations are substantial. Therefore, the role of COVID-19 vaccines in protecting high-risk individuals is crucial, and ongoing research and surveillance are imperative to refine vaccination recommendations in the ever-changing landscape of the COVID-19 endemic era. This review explores the role of COVID-19 vaccination in the upcoming COVID-19 endemic era.
Abstract
COVID-19 vaccination has played a pivotal role in coping with the COVID-19 pandemic by providing a powerful tool to curb the spread of the virus, reduce severe illness and hospitalizations, and ultimately save lives and facilitate a return to normal daily routines. As COVID-19 vaccination has become more widespread and more individuals have recovered from the infection, COVID-19 has entered an endemic disease phase. This phase is characterized by a less severe and more stable pattern of infection within certain regions, similar to the predictability of seasonal influenza. In this endemic era, COVID-19 vaccines may appear to be less important, and many people are reluctant to receive COVID-19 vaccination for various reasons, including the fear of adverse events. However, COVID-19 remains a major public health problem, in that the incidence rate of new COVID-19 infections is still high and the morbidity and mortality in high-risk populations are substantial. Therefore, the role of COVID-19 vaccines in protecting high-risk individuals is crucial, and ongoing research and surveillance are imperative to refine vaccination recommendations in the ever-changing landscape of the COVID-19 endemic era. This review explores the role of COVID-19 vaccination in the upcoming COVID-19 endemic era.
참고문헌 (32)
- Blumenthal D, "Covid-19-implications for the Health Care System", N Engl J Med, 383, pp.1483~1488 (2020)
- Bhaskaran K, "Factors associated with deaths due to COVID-19 versus other causes : population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform", Lancet Reg Health Eur, 6, pp.100109~ (2021)
- Klassen SL, "The COVID-19 pandemic : a massive threat for those living with cardiovascular disease among the poorest billion", Circulation, 142, pp.1887~1889 (2020)
- Pangallo M, "The unequal effects of the health-economy trade-off during the COVID-19 pandemic", Nat Hum Behav (2023)
- Kang Y, "Cardiovascular manifestations and treatment considerations in COVID-19", Heart, 106, pp.1132~1141 (2020)
- Xie Y, "Long-term cardiovascular outcomes of COVID-19", Nat Med, 28, pp.583~590 (2022)
- Kouhpayeh H, "Adverse events following COVID-19 vaccination : a systematic review and meta-analysis", Int Immunopharmacol, 109, pp.108906~ (2022)
- Fraiman J, "Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults", Vaccine, 40, pp.5798~5805 (2022)
- Yasmin F, "Adverse events following COVID-19 mRNA vaccines : a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia", Immun Inflamm Dis, 11, pp.e807~ (2023)
- Cho JY, "COVID-19 vaccination–related cardiovascular complications", Cardiovasc Prev Pharmacother, 5, pp.134~143 (2023)
- Antia R, "Transition to endemicity : understanding COVID-19", Immunity, 54, pp.2172~2176 (2021)
- Lavine JS, "Immunological characteristics govern the transition of COVID-19 to endemicity", Science, 371, pp.741~745 (2021)
- Krammer F, "The role of vaccines in the COVID-19 pandemic: what have we learned?", Semin Immunopathol (2023)
- Graña C, "Efficacy and safety of COVID-19 vaccines", Cochrane Database Syst Rev, 12, pp.CD015477~ (2022)
- Yang ZR, "Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies : a systematic review and meta-analysis of randomised controlled trials", Lancet Microbe, 4, pp.e236~ (2023)
- Watson OJ, "Global impact of the first year of COVID-19 vaccination : a mathematical modelling study", Lancet Infect Dis, 22, pp.1293~1302 (2022)
- Witberg G, "Myocarditis after Covid-19 vaccination in a large health care organization", N Engl J Med, 385, pp.2132~2139 (2021)
- Oster ME, "Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021", JAMA, 327, pp.331~340 (2022)
- Cho JY, "COVID-19 vaccination-related myocarditis : a Korean nationwide study", Eur Heart J, 44, pp.2234~2243 (2023)
- Pavord S, "Clinical features of vaccine-induced immune thrombocytopenia and thrombosis", N Engl J Med, 385, pp.1680~1689 (2021)
- Jaiswal V, "Cerebral venous sinus thrombosis following COVID-19 vaccination : a systematic review", J Prim Care Community Health, 13, pp.21501319221074450~ (2022)
- Mani A, "Thromboembolism after COVID-19 vaccination : a systematic review of such events in 286 patients", Ann Vasc Surg, 84, pp.12~20 (2022)
- Booth A, "Population risk factors for severe disease and mortality in COVID-19 : a global systematic review and meta-analysis", PLoS One, 16, pp.e0247461~ (2021)
- Gupta P, "Emergence of COVID-19 variants : an update", Cureus, 15, pp.e41295~ (2023)
- Wang W, "Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population : a retrospective cohort study from the TriNetX US collaborative networks", EClinicalMedicine, 53, pp.101619~ (2022)
- Notarte KI, "Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms : a systematic review", EClinicalMedicine, 53, pp.101624~ (2022)
- Andersson NW, "Comparative effectiveness of bivalent BA. 4-5 and BA. 1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries : nationwide cohort study", BMJ, 382, pp.e075286~ (2023)
- Bozkurt B, "Myocarditis with COVID-19 mRNA vaccines", Circulation, 144, pp.471~484 (2021)
- Sritharan HP, "Association between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in hospitalised patients with COVID-19", Front Cardiovasc Med, 10, pp.1224886~ (2023)
- Harrison SL, "Cardiovascular risk factors, cardiovascular disease, and COVID-19 : an umbrella review of systematic reviews", Eur Heart J Qual Care Clin Outcomes, 7, pp.330~339 (2021)
- Warren-Gash C, "Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020 : a population-based cohort study", Lancet Reg Health Eur, 27, pp.100604~ (2023)
- Kong KA, "Association between cardiovascular risk factors and the severity of coronavirus disease 2019 : nationwide epidemiological study in Korea", Front Cardiovasc Med, 8, pp.732518~ (2021)